Project Grant R01HL181226
Award Date 8/15/25
Completion Date 5/31/29
Dollars Obligated $553K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- The Regents of the University of Colorado, doing business as the University of Colorado-Denver, was awarded a $723,084 Project Grant by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to support research on the role of the PAR1/IL-17 signaling axis in the development of chronic thromboembolic pulmonary hypertension (CTEPH). The research aims to improve understanding of how different cell types and signaling pathways within chronic thrombi contribute...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- This $117,000 Project Grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports secondary analysis of 3D echocardiographic (echo) images of the right ventricle (RV) to compute 3D surface strain. The goal is to develop enhanced 3D strain analysis techniques that can provide more detailed characterization of RV deformation compared to standard 2D global longitudinal strain (GLS) measures, with the potential to improve...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $234,000 Project Grant to the University of Colorado-Denver. This 2-year grant, effective August 1, 2025 through July 31, 2027, will support secondary analysis of noninvasive imaging biomarkers to predict the early onset of single ventricle heart disease (SVD) failure. The research aims to quantify systemic and pulmonary vascular compliance through...
- This federal Project Grant award of $429,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a study to investigate the impact of selective vagal neuromodulation on heart failure indices. The 2-year project, with a start date of September 1, 2025, will be conducted by the University of Colorado-Denver. The research aims to better understand the neural interface by studying the effects of selective activation of cholinergic (efferent)...
- The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), awarded a $699,133 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The project aims to investigate the molecular insights into the actions of SGLT2 inhibitors and GLP1 agonists across the heart,...
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $169,992 Project Grant to the University of Colorado-Denver on September 18, 2025. The grant will fund a 5-year mixed methods study to inform initial antihypertensive prescribing and develop a patient self-titration intervention. The study aims to understand barriers and facilitators to initiating antihypertensive combination therapy versus stepped...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research on how tissue elasticity and viscosity modulate the signaling between macrophages and fibroblasts in cardiac fibrosis. The $231,552 award, granted to the University of California, San Diego, will fund research to investigate the effects of mechanical stimuli on macrophage-fibroblast interactions and explore the role of a changing mechanical...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $760,083 Project Grant to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to investigate the role of the protein C system in trauma-induced coagulopathy and thromboinflammation, with the goal of developing targeted therapies. The project will examine the mechanisms underlying the protein C system's dual...